A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT06973187 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

DRUG: BGB-16673
DRUG: Pirtobrutinib

Sponsor

BeOne Medicines